Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 51% Improvement Relative Risk Ventilation 41% Hospitalization 40% Metformin for COVID-19  Wong et al.  Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 39,616 patients in the USA Lower mortality (p<0.0001) and ventilation (p<0.0001) c19early.org Wong et al., Diabetes Care, February 2022 Favors metformin Favors control

Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database

Wong et al., Diabetes Care, doi:10.2337/dc21-2186
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now known with p < 0.00000000001 from 89 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
N3C retrospective 39,616 COVID-19 patients with diabetes in the USA, showing lower mortality, ventilation, and hospitalization with metformin use.
risk of death, 51.0% lower, HR 0.49, p < 0.001, treatment 10,408, control 29,208, Cox proportional hazards.
risk of mechanical ventilation, 41.0% lower, OR 0.59, p < 0.001, treatment 10,408, control 29,208, adjusted per study, multivariable, RR approximated with OR.
risk of hospitalization, 40.0% lower, OR 0.60, p < 0.001, treatment 10,408, control 29,208, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wong et al., 24 Feb 2022, retrospective, USA, peer-reviewed, 15 authors.
This PaperMetforminAll
Abstract: Diabetes Care Rachel Wong,1 Margaret Hall,1 Rohith Vaddavalli,2 Adit Anand,1 Neha Arora,3 Carolyn T. Bramante,4 Victor Garcia,1 Steven Johnson,5 Mary Saltz,1 Jena S. Tronieri,6 Yun Jae Yoo,1 John B. Buse,7,8 Joel Saltz,1 Joshua Miller,3 and Richard Moffitt,1 for the N3C Consortium* OBJECTIVE The purpose of the study is to evaluate the relationship between HbA1c and severity of coronavirus disease 2019 (COVID-19) outcomes in patients with type 2 diabetes (T2D) with acute COVID-19 infection. RESEARCH DESIGN AND METHODS We conducted a retrospective study using observational data from the National COVID Cohort Collaborative (N3C), a longitudinal, multicenter U.S. cohort of patients with COVID-19 infection. Patients were ‡18 years old with T2D and confirmed COVID-19 infection by laboratory testing or diagnosis code. The primary outcome was 30-day mortality following the date of COVID-19 diagnosis. Secondary outcomes included need for invasive ventilation or extracorporeal membrane oxygenation (ECMO), hospitalization within 7 days before or 30 days after COVID-19 diagnosis, and length of stay (LOS) for patients who were hospitalized. RESULTS The study included 39,616 patients (50.9% female, 55.4% White, 26.4% Black or African American, and 16.1% Hispanic or Latino, with mean ± SD age 62.1 ± 13.9 years and mean ± SD HbA1c 7.6% ± 2.0). There was an increasing risk of hospitalization with incrementally higher HbA1c levels, but risk of death plateaued at HbA1c >8%, and risk of invasive ventilation or ECMO plateaued >9%. There was no significant difference in LOS across HbA1c levels. CONCLUSIONS 1 Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY 2 Department of Computer Science, Stony Brook University, Stony Brook, NY 3 Division of Endocrinology and Metabolism, Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 4 Division of General Internal Medicine, University of Minnesota Medical School, Minneapolis, MN 5 Institute for Health Informatics, University of Minnesota, Minneapolis, MN 6 Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 7 Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 8 North Carolina Translational and Clinical Sciences Institute, University of North Carolina School of Medicine, Chapel Hill, NC Corresponding author: Rachel Wong, rachel. wong@stonybrookmedicine.edu Received 20 October 2021 and accepted 28 January 2022 This article contains supplementary material online at https://doi.org/10.2337/figshare.19119302. In a large, multicenter cohort of patients in the U.S. with T2D and COVID-19 infection, risk of hospitalization increased with incrementally higher HbA1c levels. Risk of death and invasive ventilation also increased but plateaued at different levels of glycemic control. J.M. and R.M. contributed equally. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed >4 million lives worldwide since the first reported case of coronavirus disease-2019 (COVID-19) in December 2019 (1). Diabetes has been implicated as a risk factor for increased mortality and morbidity in patients with COVID-19 infection, with a higher prevalence of diabetes reported in patients with severe outcomes, including © 2022 by the American Diabetes Association. Readers may use this article as long as the work is properly..
{ 'DOI': '10.2337/dc21-2186', 'ISSN': ['0149-5992', '1935-5548'], 'URL': 'http://dx.doi.org/10.2337/dc21-2186', 'abstract': '<jats:sec>\n' ' <jats:title>OBJECTIVE</jats:title>\n' ' <jats:p>The purpose of the study is to evaluate the relationship between ' 'HbA1c and severity of coronavirus disease 2019 (COVID-19) outcomes in patients with type 2 ' 'diabetes (T2D) with acute COVID-19 infection.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>RESEARCH DESIGN AND METHODS</jats:title>\n' ' <jats:p>We conducted a retrospective study using observational data from ' 'the National COVID Cohort Collaborative (N3C), a longitudinal, multicenter U.S. cohort of ' 'patients with COVID-19 infection. Patients were ≥18 years old with T2D and confirmed COVID-19 ' 'infection by laboratory testing or diagnosis code. The primary outcome was 30-day mortality ' 'following the date of COVID-19 diagnosis. Secondary outcomes included need for invasive ' 'ventilation or extracorporeal membrane oxygenation (ECMO), hospitalization within 7 days ' 'before or 30 days after COVID-19 diagnosis, and length of stay (LOS) for patients who were ' 'hospitalized.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>RESULTS</jats:title>\n' ' <jats:p>The study included 39,616 patients (50.9% female, 55.4% White, ' '26.4% Black or African American, and 16.1% Hispanic or Latino, with mean ± SD age 62.1 ± 13.9 ' 'years and mean ± SD HbA1c 7.6% ± 2.0). There was an increasing risk of hospitalization with ' 'incrementally higher HbA1c levels, but risk of death plateaued at HbA1c &amp;gt;8%, and risk ' 'of invasive ventilation or ECMO plateaued &amp;gt;9%. There was no significant difference in ' 'LOS across HbA1c levels.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>CONCLUSIONS</jats:title>\n' ' <jats:p>In a large, multicenter cohort of patients in the U.S. with T2D and ' 'COVID-19 infection, risk of hospitalization increased with incrementally higher HbA1c levels. ' 'Risk of death and invasive ventilation also increased but plateaued at different levels of ' 'glycemic control.</jats:p>\n' ' </jats:sec>', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-3108-7324', 'affiliation': [ { 'name': 'Department of Biomedical Informatics, Stony Brook University, ' 'Stony Brook, NY'}], 'authenticated-orcid': False, 'family': 'Wong', 'given': 'Rachel', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Department of Biomedical Informatics, Stony Brook University, ' 'Stony Brook, NY'}], 'family': 'Hall', 'given': 'Margaret', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Computer Science, Stony Brook University, Stony ' 'Brook, NY'}], 'family': 'Vaddavalli', 'given': 'Rohith', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biomedical Informatics, Stony Brook University, ' 'Stony Brook, NY'}], 'family': 'Anand', 'given': 'Adit', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Division of Endocrinology and Metabolism, Department of ' 'Medicine, Renaissance School of Medicine at Stony Brook ' 'University, Stony Brook, NY'}], 'family': 'Arora', 'given': 'Neha', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-5858-2080', 'affiliation': [ { 'name': 'Division of General Internal Medicine, University of Minnesota ' 'Medical School, Minneapolis, MN'}], 'authenticated-orcid': False, 'family': 'Bramante', 'given': 'Carolyn T.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biomedical Informatics, Stony Brook University, ' 'Stony Brook, NY'}], 'family': 'Garcia', 'given': 'Victor', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Institute for Health Informatics, University of Minnesota, ' 'Minneapolis, MN'}], 'family': 'Johnson', 'given': 'Steven', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biomedical Informatics, Stony Brook University, ' 'Stony Brook, NY'}], 'family': 'Saltz', 'given': 'Mary', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Psychiatry, Perelman School of Medicine at the ' 'University of Pennsylvania, Philadelphia, PA'}], 'family': 'Tronieri', 'given': 'Jena S.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biomedical Informatics, Stony Brook University, ' 'Stony Brook, NY'}], 'family': 'Yoo', 'given': 'Yun Jae', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Division of Endocrinology and Metabolism, Department of ' 'Medicine, University of North Carolina School of Medicine, ' 'Chapel Hill, NC'}, { 'name': 'North Carolina Translational and Clinical Sciences Institute, ' 'University of North Carolina School of Medicine, Chapel Hill, ' 'NC'}], 'family': 'Buse', 'given': 'John B.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biomedical Informatics, Stony Brook University, ' 'Stony Brook, NY'}], 'family': 'Saltz', 'given': 'Joel', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-9512-461X', 'affiliation': [ { 'name': 'Division of Endocrinology and Metabolism, Department of ' 'Medicine, Renaissance School of Medicine at Stony Brook ' 'University, Stony Brook, NY'}], 'authenticated-orcid': False, 'family': 'Miller', 'given': 'Joshua', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biomedical Informatics, Stony Brook University, ' 'Stony Brook, NY'}], 'family': 'Moffitt', 'given': 'Richard', 'sequence': 'additional'}], 'container-title': ['Diabetes Care'], 'content-domain': {'crossmark-restriction': True, 'domain': ['diabetesjournals.org']}, 'created': {'date-parts': [[2022, 2, 24]], 'date-time': '2022-02-24T18:38:42Z', 'timestamp': 1645727922000}, 'deposited': { 'date-parts': [[2022, 3, 13]], 'date-time': '2022-03-13T11:39:59Z', 'timestamp': 1647171599000}, 'indexed': {'date-parts': [[2022, 3, 14]], 'date-time': '2022-03-14T09:40:56Z', 'timestamp': 1647250856371}, 'is-referenced-by-count': 0, 'issn-type': [{'type': 'print', 'value': '0149-5992'}, {'type': 'electronic', 'value': '1935-5548'}], 'issued': {'date-parts': [[2022, 2, 24]]}, 'language': 'en', 'license': [ { 'URL': 'https://www.diabetesjournals.org/journals/pages/license', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 2, 24]], 'date-time': '2022-02-24T00:00:00Z', 'timestamp': 1645660800000}}], 'link': [ { 'URL': 'https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc21-2186/670185/dc212186.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'https://diabetesjournals.org/care/article-pdf/doi/10.2337/dc21-2186/670185/dc212186.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '1167', 'original-title': [], 'prefix': '10.2337', 'published': {'date-parts': [[2022, 2, 24]]}, 'published-online': {'date-parts': [[2022, 2, 24]]}, 'publisher': 'American Diabetes Association', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': { 'primary': { 'URL': 'https://diabetesjournals.org/care/article/doi/10.2337/dc21-2186/144605/Glycemic-Control-and-Clinical-Outcomes-in-U-S'}}, 'score': 1, 'short-container-title': [], 'short-title': [], 'source': 'Crossref', 'subject': [ 'Advanced and Specialized Nursing', 'Endocrinology, Diabetes and Metabolism', 'Internal Medicine'], 'subtitle': [], 'title': [ 'Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National ' 'COVID Cohort Collaborative (N3C) Database'], 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.2337/ada-journal-policies'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit